Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 15/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RNF4 | P78317 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313304 | 0.83 | LTA4H (0.72) | LTA4H | |
| SCHEMBL5661963 | 0.81 | LTA4H (0.61) | LTA4HALDH1A1KDM4E | |
| SCHEMBL5662447 | 0.81 | RECQL (0.57) | LTA4HGAAALDH1A1KDM4ELMNA | |
| SCHEMBL5661392 | 0.80 | LTA4H (0.57) | LTA4HEP300NCOA1NCOA3LMNA | |
| SCHEMBL5660215 | 0.78 | LTA4H (0.82) | LTA4HGAAALDH1A1KDM4EPOLB | |
| SCHEMBL5661515 | 0.77 | LTA4H (0.80) | LTA4H | |
| SCHEMBL5659348 | 0.77 | RECQL (0.55) | LTA4HGAAALDH1A1KDM4ELMNA | |
| SCHEMBL5661889 | 0.75 | LTA4H (0.85) | LTA4HGAAALDH1A1KDM4EPOLB | |
| SCHEMBL5664362 | 0.73 | LTA4H (1.00) | LTA4HSMN1; SMN2 | |
| SCHEMBL5660267 | 0.73 | LTA4H (0.95) | LTA4HALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885EP300 2175/4885NCOA1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.